We demonstrate three approaches (PAI1-targeted, PLK1-targeted, and epigenetics-targeted) to restore HER2 therapy sensitivity in a panel of fibroblast-protected HER2+ breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.